Aelis Farma SA (ENXTPA: AELIS)
Health Care · Biotechnology · FR
€1.06
-0.93% today · -17.2% 1Y
Aelis Farma SA (ENXTPA: AELIS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.83M and employs 16 people.
Over the last twelve months the share price has lost 17.2%, trading between 0.95 and 2.30.
Tweenvest scores Aelis Farma SA across four factors: quality 35/100, value 52/100. Its strongest factor is value.
AELIS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.83M
- Revenue (TTM)
- $2.45M
- P/E
- —
- EPS
- -0.47
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- €2.30
- 52-week low
- €0.95
- Avg volume (3M)
- —
- Shares outstanding
- 13.60M
- Employees
- 16
- Next earnings
- —
About Aelis Farma SA
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
- ISIN
- FR0014007ZB4
- Founded
- 2013
- Listed since
- Feb 18, 2022
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.